Invesco
STLN

Invesco’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Invesco’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$114K Sell
37,219
-9,793
-21% -$30K ﹤0.01% 3607
2025
Q4 		$167K Buy
47,012
+8,425
+22% +$31.2K ﹤0.01% 3569
2025
Q3 		$135K Sell
38,587
-121
-0.3% -$415 ﹤0.01% 3640
2025
Q2 		$79.4K Buy
+38,708
New +$96.8K ﹤0.01% 3678
2023
Q2 		– Sell
-11,398
Closed -$7.73K – 3947
2023
Q1 		$7.73K Buy
11,398
+241
+2% +$307 ﹤0.01% 3846
2022
Q4 		$18.4K Sell
11,157
-1,485
-12% -$4.17K ﹤0.01% 3976
2022
Q3 		$58K Buy
+12,642
New +$74.3K ﹤0.01% 3903

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco's STLN Position: Q1 2026 in Review

Invesco reduced its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 21% in Q1 2026, selling an estimated $30K and leaving 37,219 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #3607.

Invesco first reported a position in STLN in Q3 2022 and has held it in 7 quarters since. The position peaked at $167K in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Invesco held 37,219 shares of Starling Oncology Institute, Inc. Common Stock worth $114K as of Q1 2026.
  • Invesco sold 9,793 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $30K.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3607 holding.
  • Invesco first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2022 and has held it in 7 quarters since.
  • Invesco's Starling Oncology Institute, Inc. Common Stock position peaked at $167K in Q4 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.